199 related articles for article (PubMed ID: 23021410)
1. An approach for diagnosing plasma cell myeloma by three-color flow cytometry based on kappa/lambda ratios of CD38-gated CD138(+) cells.
Nakayama S; Yokote T; Hirata Y; Iwaki K; Akioka T; Miyoshi T; Takayama A; Nishiwaki U; Masuda Y; Ikemoto T; Tanaka H; Nishimura Y; Tsuji M; Hanafusa T
Diagn Pathol; 2012 Sep; 7():131. PubMed ID: 23021410
[TBL] [Abstract][Full Text] [Related]
2. An approach for plasma cell myeloma diagnosis by two-color flow cytometry based on kappa/lambda ratios of CD38-gated plasma cells.
Nakayama S; Yokote T; Hirata Y; Iwaki K; Akioka T; Miyoshi T; Takayama A; Nishiwaki U; Masuda Y; Ikemoto T; Tanaka H; Nishimura Y; Tsuji M; Hanafusa T
Int J Immunopathol Pharmacol; 2013; 26(2):479-83. PubMed ID: 23755763
[TBL] [Abstract][Full Text] [Related]
3. Immunohistological diagnosis of plasma cell myeloma based on cytoplasmic kappa/lambda ratio of CD138-positive plasma cells.
Nakayama-Ichiyama S; Yokote T; Hirata Y; Iwaki K; Akioka T; Miyoshi T; Takayama A; Nishiwaki U; Masuda Y; Nishimura Y; Tsuji M; Hanafusa T
Leuk Lymphoma; 2012 Nov; 53(11):2205-9. PubMed ID: 22506669
[TBL] [Abstract][Full Text] [Related]
4. Immunohistological analysis in diagnosis of plasma cell myeloma based on cytoplasmic kappa/lambda ratio of CD38-positive plasma cells.
Nakayama S; Yokote T; Hirata Y; Iwaki K; Akioka T; Miyoshi T; Nishiwaki U; Masuda Y; Hiraoka N; Takayama A; Nishimura Y; Tsuji M; Hanafusa T
Hematology; 2012 Nov; 17(6):317-20. PubMed ID: 23168070
[TBL] [Abstract][Full Text] [Related]
5. Biphenotypic plasma cell myeloma: two cases of plasma cell neoplasm with a coexpression of kappa and lambda light chains.
Jiwani S; Bornhost J; Alapat D
Int J Clin Exp Pathol; 2015; 8(7):8536-44. PubMed ID: 26339430
[TBL] [Abstract][Full Text] [Related]
6. The cut-offs for kappa/lambda ratio in bone marrow immunohistochemistry for the diagnosis of multiple myeloma.
Warnnissorn AN; Treetipsatit J; Limvorapitak W
Hematology; 2020 Dec; 25(1):292-298. PubMed ID: 32772824
[No Abstract] [Full Text] [Related]
7. [Comparison and analysis of minimal residual disease in multiple myeloma patients detected by 4-color and 8-color fluorescence antibody panels].
Wang YZ; Lu J; Hao L; Chang Y; He LL; Huang XJ; Liu YR
Zhonghua Xue Ye Xue Za Zhi; 2017 Apr; 38(4):272-278. PubMed ID: 28468086
[No Abstract] [Full Text] [Related]
8. Inability of a monoclonal anti-light chain antibody to detect clonal plasma cells in a patient with multiple myeloma by multicolor flow cytometry.
van Velzen JF; van den Blink D; Bloem AC
Cytometry B Clin Cytom; 2013; 84(1):30-2. PubMed ID: 23019187
[TBL] [Abstract][Full Text] [Related]
9. A novel multiparametric approach for analysis of cytoplasmic immunoglobulin light chains by flow cytometry.
Chang CC; Schur BC; Kampalath B; Lindholm P; Becker CG; Vesole DH
Mod Pathol; 2001 Oct; 14(10):1015-21. PubMed ID: 11598172
[TBL] [Abstract][Full Text] [Related]
10. Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases.
Pojero F; Flores-Montero J; Sanoja L; Pérez JJ; Puig N; Paiva B; Bottcher S; van Dongen JJ; Orfao A;
Cytometry B Clin Cytom; 2016 Jan; 90(1):91-100. PubMed ID: 26130131
[TBL] [Abstract][Full Text] [Related]
11. The evaluation of minimal residual disease in multiple myeloma by fluorescent molecular beacons in real time PCR of IgH gene rearrangements and correlation with flow cytometry.
Kara IO; Duman BB; Afsar CU
J BUON; 2013; 18(2):442-7. PubMed ID: 23818359
[TBL] [Abstract][Full Text] [Related]
12. Tc-99m methoxyisobutylisonitrile bone marrow imaging for predicting the levels of myeloma cells in bone marrow in multiple myeloma: correlation with CD38/CD138 expressing myeloma cells.
Ak I; Aslan V; Vardareli E; Gülbaş Z
Ann Hematol; 2003 Feb; 82(2):88-92. PubMed ID: 12601486
[TBL] [Abstract][Full Text] [Related]
13. Kappa and lambda light chain mRNA in situ hybridization compared to flow cytometry and immunohistochemistry in B cell lymphomas.
Rimsza LM; Day WA; McGinn S; Pedata A; Natkunam Y; Warnke R; Cook JR; Marafioti T; Grogan TM
Diagn Pathol; 2014 Jul; 9():144. PubMed ID: 25047073
[TBL] [Abstract][Full Text] [Related]
14. Immunophenotyping of plasma cells.
Rawstron AC
Curr Protoc Cytom; 2006 May; Chapter 6():Unit6.23. PubMed ID: 18770841
[TBL] [Abstract][Full Text] [Related]
15. CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells.
Kim D; Park CY; Medeiros BC; Weissman IL
Leukemia; 2012 Dec; 26(12):2530-7. PubMed ID: 22733078
[TBL] [Abstract][Full Text] [Related]
16. Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma.
Cengiz A; Arda HÜ; Döğer F; Yavaşoğlu İ; Yürekli Y; Bolaman AZ
Turk J Haematol; 2018 Aug; 35(3):175-180. PubMed ID: 29806594
[TBL] [Abstract][Full Text] [Related]
17. Double CD38
Mykytiv V; Alwaheed A; Mohd Hashim NA
Hematol Oncol Stem Cell Ther; 2019 Mar; 12(1):64-66. PubMed ID: 29079129
[TBL] [Abstract][Full Text] [Related]
18. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.
Kara IO; Sahin B; Paydas S; Cetiner S
Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184
[TBL] [Abstract][Full Text] [Related]
19. Increased circulating plasma cells detected by flow cytometry predicts poor prognosis in patients with plasma cell myeloma.
Bae MH; Park CJ; Kim BH; Cho YU; Jang S; Lee DH; Seo EJ; Yoon DH; Lee JH; Suh C
Cytometry B Clin Cytom; 2018 May; 94(3):493-499. PubMed ID: 29220877
[TBL] [Abstract][Full Text] [Related]
20. Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma.
Liu D; Lin P; Hu Y; Zhou Y; Tang G; Powers L; Medeiros LJ; Jorgensen JL; Wang SA
J Clin Pathol; 2012 Sep; 65(9):823-9. PubMed ID: 22685235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
